Price Alert

Asahi Kasei Corporation (AHKSY)

OTC: AHKSY · Real-Time Price · USD

16.30

-0.08 (-0.49%)

At close: Sep 04, 2025, 3:52 PM

16.40

0.61%

Pre-market: Sep 04, 2025, 10:55 AM EDT

-0.49% (1D)

Bid	16.28
Market Cap	11.18B
Revenue (ttm)	3,037.3B
Net Income (ttm)	135B
EPS (ttm)	1.33
PE Ratio (ttm)	12.26
Forward PE	0.08
Analyst	n/a

Ask	16.4
Volume	700
Avg. Volume (20D)	19,053
Open	16.21
Previous Close	16.38
Day's Range	16.21 - 16.40
52-Week Range	12.12 - 17.28
Beta	0.42

About AHKSY

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AHKSY

Website n/a

Full Company Profile

News

1 day ago · businesswire.com

Asahi Kasei to Unveil PFAS-Free Polyamides and CFRP Recycling Technology at K 2025

DUESSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei will unveil its newest innovation in PFAS-free polyamides and recycling technology at K 2025 in Hall 8a, Booth E23.

2 days ago · businesswire.com

Bondalti Chemicals Starts Operation of Chlor-Alkali Plant in Portugal With Asahi Kasei's Electrolyzer System

TOKYO--(BUSINESS WIRE)--Bondalti Chemicals has started operation of its chlor-alkali production facility in Estarreja, Portugal.

1 month ago · businesswire.com

Asahi Kasei Expands Planova™ Production with New Spinning Plant, Strengthening Life Science's Global Bioprocess Supply Capabilities

CHELMSFORD, Mass. & NOVI, Mich. & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--Asahi Kasei Life Science announced plans to construct a new spinning plant for its Planova™ virus removal filters in Jap...

2 months ago · businesswire.com

Asahi Kasei Pharma Starts Phase III Study of Promising CIPN Prevention Therapy, ART-123 (Recomodulin™), to Enhance Treatment Options Worldwide

CHELMSFORD, Mass. & NOVI, Mich. & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan for CIPN.